Pantocalcin tablets 250mg №10×5

Name Pantocalcin tab. 250mg in box No. 10×5 Composition 1 tablet contains: active substance: hopantenic acid (hopantenic acid or calcium salt of hopantenic acid) – 0.25 g (250 mg) or 0.5 g (500 mg); excipients: magnesium hydroxycarbonate, calcium stearate, talc, potato starch. Pharmacotherapeutic group Other psychostimulants and nootropics. ATX code: N06BX. Pharmacological properties Pharmacodynamics The spectrum of action of Pantocalcin® is associated with the presence of gamma-aminobutyric acid in its structure. The mechanism of action is due to the direct influence of Pantogam on the GABAB-receptor-channel complex. The drug has a nootropic and anticonvulsant effect. Pantocalcin® increases the resistance of the brain to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, and activates mental and physical performance. Improves GABA metabolism in chronic alcohol intoxication and after ethanol withdrawal. It is able to inhibit acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically increased cystic reflex and detrusor tone. Pharmacokinetics Absorption Rapidly absorbed from the gastrointestinal tract. The time to reach the maximum concentration in blood plasma is 1 hour. Distribution The highest concentrations are in the liver, kidneys, in the wall of the stomach, skin. Penetrates through the blood-brain barrier. Metabolism Not metabolized. Excretion Excreted unchanged within 48 hours (67.5% of the accepted dose – with urine, 28.5% – with feces) Pharmacokinetics in special groups of patients (elderly patients, children, adolescents, patients with renal insufficiency, patients with liver failure) has not been studied. Indications for use: cognitive impairment in organic brain lesions and neurotic disorders; as part of complex therapy for cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels; senile dementia (initial form), residual organic brain lesions in adults and the elderly; cerebral organic insufficiency in patients with schizophrenia (in combination with antipsychotics, antidepressants); extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (Huntington’s chorea, hepatocerebral dystrophy, Parkinson, etc.); the consequences of neuroinfections and traumatic brain injuries (as part of complex therapy); to correct the side effects of neuroleptics and for prophylactic purposes simultaneously as a “cover therapy”; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic); epilepsy with a slowdown in mental processes (in combination with anticonvulsants); psycho-emotional overload, decreased mental and physical performance; to improve concentration and memory; urination disorders: enuresis, daytime urinary incontinence, pollakiuria, imperative urges; children with mental retardation (delayed mental, speech, motor development, or a combination thereof); children’s cerebral palsy; stuttering (mainly clonic form); epilepsy (as part of combination therapy with anticonvulsants, especially in polymorphic seizures and small epileptic seizures). Dosage and administration Inside, 15-30 minutes after eating. A single dose for adults is 0.5-1 g, for children – 0.25-0.5 g, a daily dose for adults – 1.5-3 g, for children – 0.75-3 g. The duration of the course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a second course of treatment is possible. Children with mental insufficiency: 0.5 g 4-6 times a day, daily for 3 months, with delayed speech development – 0.5 g 3-4 times a day for 2-3 months. In case of neuroleptic syndrome (as a corrector of side effects of antipsychotic drugs): adults – 0.5-1 g 3 times a day, children – 0.25-0.5 g 3-4 times a day. The duration of the course of treatment is 1-3 months. For epilepsy: children 0.25-0.5 g 3-4 times a day, adults 0.5-1 g 3-4 times a day daily for a long time (up to 6 months). With hyperkinesias (tics): for children, 0.25-0.5 g 3-6 times a day, daily for 1-4 months, for adults – 1.5-3 g per day, daily for 1-5 months. For urination disorders: adults 0.5-1 g 2-3 times a day (daily dose 2-3 g), children – 0.25-0.5 g (daily dose 25-50 mg / kg). The duration of the course of treatment is from 2 weeks to 3 months (depending on the severity of the disorders and the therapeutic effect). With the consequences of neuroinfections and craniocerebral injuries: 0.25 g 3-4 times a day. To restore working capacity at increased loads and asthenic conditions: 0.25 g 3 times a day. Children from 3 to 5 years old take tablets only under the supervision of adults. In the absence of the skill of taking pills, this dosage form is unsuitable for children. The use of this drug is possible only after consulting a doctor! If you forget to take a medicine, do not take a double dose to make up for the missed one! Do not stop taking Pantocalcin® without first consulting your doctor! If you have any doubts or questions, please contact your doctor. Side effects Allergic reactions are possible (rhinitis, conjunctivitis, skin rashes). In this case, reduce the dose or cancel the drug. Sleep disturbances or drowsiness, noise in the head – these symptoms are usually short-lived and do not require discontinuation of the drug. If side effects occur, tell your doctor about it. This applies to all possible side effects, including those not described in this package insert. Contraindications Hypersensitivity; acute renal failure; pregnancy (I trimester), lactation, children under 3 years of age (for this dosage form). OverdoseSymptoms: increased side effects. Treatment: gastric lavage, activated charcoal, symptomatic therapy. Precautions In long-term treatment, the simultaneous administration of Pantocalcin® with other nootropic drugs and agents that stimulate the central nervous system (CNS) is not recommended. In case of allergic reactions, Pantocalcin® is canceled. Use during pregnancy and lactation If you are pregnant or breastfeeding, if you think you are pregnant or do not rule out the possibility of pregnancy, tell your doctor. Hopantenic acid is contraindicated for use in the first trimester of pregnancy. Experimental studies have shown that hopantenic acid does not have a teratogenic and embryotoxic effect. The use of the drug in the II and III trimester of pregnancy is possible according to indications after consultation with a doctor. Studies in women during breastfeeding have not been conducted, therefore, if necessary, the use of the drug during lactation should stop breastfeeding. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms Care should be taken when driving vehicles or other potentially dangerous mechanisms at the beginning of therapy due to possible transient side effects (drowsiness, noise in the head). Interaction with other drugs If you are currently or have recently taken other drugs, tell your doctor. Prolongs the action of barbiturates; enhances the effects of drugs that stimulate the central nervous system, anticonvulsant drugs, the action of local anesthetics (procaine). Prevents side effects of phenobarbital, carbamazepine, antipsychotics (neuroleptics). The action of hopantenic acid is enhanced in combination with glycine, ksidifon. Storage conditions In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life Shelf life is 4 years. Do not use after the expiration date. Leave conditions By prescription. Packaging Tablets of 250 mg and 500 mg. 10 tablets in a blister pack with perforations made of PVC film and printed lacquered aluminum foil. 5 blister packs, together with instructions for use, are placed in a cardboard box. Buy Pantocalcin tablets 250mg No. 10×5 Price for Pantocalcin tablets 250mg No. 10×5